Drug interactions
Buprenorphine transdermal + Pazopanib
Severity: Moderate
Buprenorphine transdermal and Pazopanib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pazopanib can prolong the QT interval, and transdermal buprenorphine carries a labeled QTc warning. Combined use may increase the likelihood of ventricular arrhythmia, particularly at higher patch strengths.
What this interaction means in plain words
Buprenorphine transdermal and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Additive pharmacodynamic QT prolongation.
What to do
Obtain a baseline ECG and correct hypokalemia or hypomagnesemia. Monitor the ECG during treatment and keep the patch strength as low as possible.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine transdermal and Pazopanib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Pazopanib
- Adagrasib + Pazopanib Major
- Amiodarone + Pazopanib Major
- Amisulpride + Pazopanib Major
- Amobarbital + Pazopanib Major
- Anagrelide + Pazopanib Major
- Apalutamide + Pazopanib Major
Frequently asked questions
Can I take Buprenorphine transdermal with Pazopanib?
MediHelp rates the interaction as moderate. Buprenorphine transdermal and Pazopanib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Pazopanib can prolong the QT interval, and transdermal buprenorphine carries a labeled QTc warning. Combined use may increase the likelihood of ventricular arrhythmia, particularly at higher patch strengths.
How serious is the interaction between Buprenorphine transdermal and Pazopanib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Obtain a baseline ECG and correct hypokalemia or hypomagnesemia. Monitor the ECG during treatment and keep the patch strength as low as possible.
What other medicines interact with Pazopanib?
MediHelp also lists interactions of Pazopanib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Pazopanib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
